GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK'786
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.
New Bayer U.S. Innovation Center starts its operations
- Details
- Category: Bayer
The U.S. Innovation Center of Bayer HealthCare's pharmaceutical division has started its operations in San Francisco's Mission Bay life sciences hub. At the same time the company announced a master agreement for research collaborations with the University of California, San Francisco (UCSF).
People to Actively Manage Their Type 2 Diabetes
- Details
- Category: Bristol-Myers Squibb
The American Association of Clinical Endocrinologists (AACE) and its educational arm - the American College of Endocrinology (ACE) - in partnership with Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), announced a new public health initiative for people with type 2 diabetes mellitus called The Type 2 Talk:
Genzyme Financial Recovery Continues in Fourth Quarter
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported that preliminary fourth-quarter revenue grew 23 percent to $1.15 billion from $938 million in the fourth quarter of 2009. For the year, revenue was $4.1 billion compared with $4.0 billion in 2009.
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse®
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results from a study of Vyvanse® (lisdexamfetamine dimesylate), assessing its effect in a model for Excessive Daytime Sleepiness (EDS).
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold
- Details
- Category: Abbott
Abbott (NYSE: ABT) has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years,
Genzyme Statement on Discussions With Sanofi-Aventis
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported today that discussions between its financial advisors and financial advisors for Sanofi-Aventis are continuing and have expanded to include representatives of both companies.
More Pharma News ...
- US Food and Drug Administration extend review timeline for vandetanib
- KOMBIGLYZE™ XR Now Available in U.S. Pharmacies
- FDA grants supplemental approval for ACTEMRA
- Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases
- Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines
- Merck KGaA Acquires Supplier to Biopharma Industry in China
- GSK responds to 60 Minutes | Related Video